Yes, if you purchased Hetero valsartan—a generic blood pressure medication—during the contamination period, you are eligible to claim compensation from an $11.37 million class action settlement. The settlement covers individuals and entities who bought Hetero valsartan manufactured by Hetero Labs (distributed under the Camber Pharmaceuticals label) between January 1, 2016 and the present, though the contamination that triggered the recall occurred specifically between May 1 and July 31, 2018. For example, if you filled a prescription for generic valsartan at your local pharmacy in June 2018 or purchased it through a mail-order service during that window, you likely have a valid claim.
The settlement addresses contamination of valsartan with NDMA (N-nitrosodimethylamine), a chemical classified by the FDA and World Health Organization as a probable human carcinogen. This is part of a larger $15.26 million multi-drug settlement that also covers contaminated irbesartan made by Aurobindo and losartan made by Vivimed, all medications used to treat high blood pressure. Eligible claimants can receive up to $40 per 30-day supply of the medication they purchased, with a maximum of $120 total per consumer, depending on the number of prescriptions they can document.
Table of Contents
- Why Was Hetero Valsartan Recalled and What Makes You Eligible?
- Understanding the Settlement Fund and Payment Structure
- Critical Deadlines and Settlement Timeline You Cannot Miss
- How to File a Claim and What Documentation You’ll Need
- Important Limitations That Could Reduce or Eliminate Your Payment
- How This Hetero Settlement Fits Into the Larger Blood Pressure Drug Contamination Crisis
- What Settlement Administrators Learned From Past Drug Contamination Cases
- Conclusion
Why Was Hetero Valsartan Recalled and What Makes You Eligible?
The Hetero valsartan recall stemmed from the discovery of unacceptable levels of NDMA in the finished product, which violated FDA safety standards. NDMA is a chemical byproduct that can form during the manufacturing process if proper protocols aren’t followed, and prolonged exposure to it has been linked to cancer in animal studies. The FDA identified the contamination during routine testing and issued recalls for multiple manufacturers’ valsartan products between 2018 and 2019. Hetero Labs, a major generic pharmaceutical manufacturer based in India, was among the manufacturers whose products were found to be contaminated.
Eligibility for this settlement is straightforward: you must have purchased Hetero valsartan at any point from January 1, 2016 through the present, either through retail pharmacies, mail-order services, or insurance coverage. The settlement covers both individual consumers and entities like nursing homes, clinics, or other healthcare facilities. To illustrate the breadth of this settlement, a 65-year-old retiree who bought three months’ worth of generic valsartan at CVS in March 2018 would be eligible, as would a small urgent care clinic that purchased the medication in bulk. However, people who took brand-name Valsertan (the brand-name version) are not eligible—only generic versions manufactured by Hetero Labs qualify.
Understanding the Settlement Fund and Payment Structure
The $11.37 million allocated specifically for Hetero valsartan claims will be divided among all eligible claimants based on the amount of medication they purchased. The settlement is structured as a per-unit payout: claimants receive up to $40 for each 30-day supply of valsartan they can document purchasing. If you have receipts or pharmacy records showing you purchased six 30-day supplies, you could claim up to $240, but the settlement imposes a cap of $120 maximum per consumer, meaning your claim would be limited to that amount. This cap is an important limitation—even if you took the medication for years, you cannot receive more than $120 regardless of how many prescriptions you can verify.
The payment amount per 30-day supply may be prorated if the settlement fund does not have enough money to pay all claims in full. For example, if all eligible claims total $25 million but only $11.37 million is available, each claim might be reduced proportionally—what was valued at $40 per supply might become $22 per supply. This is a common scenario in class action settlements and represents a significant limitation that claimants should understand before filing. If you took generic valsartan for a decade or more, you still cannot exceed the $120 cap, and you may receive less per unit if the fund is oversubscribed.
Critical Deadlines and Settlement Timeline You Cannot Miss
The most important date for this settlement is June 2, 2026, which is the combined deadline for opting out, filing objections, and submitting claims. If you do not submit a claim by this date, you will be forever barred from receiving any compensation from this settlement, and you will be bound by the terms of the settlement regardless of how you feel about it. Claim forms became available on April 2, 2026, giving claimants roughly two months to gather documentation and submit their paperwork. The deadline is not negotiable—late claims are typically rejected without exception, so this is a critical date to mark on your calendar. The final approval hearing is scheduled for June 30, 2026, at 10:00 a.m.
in the U.S. District Court for the District of New Jersey. At this hearing, the judge will review the settlement terms, consider any objections that were filed, and determine whether the settlement is fair and reasonable. This hearing is public, and in some cases, objectors may present arguments before the court. For most claimants, the takeaway is simple: if you plan to claim compensation, submit your claim by June 2, 2026. Missing this deadline means forfeiting your right to payment entirely, even by a single day.
How to File a Claim and What Documentation You’ll Need
To file a claim in the Hetero valsartan settlement, you must complete the official claim form (available through the settlement website) and provide documentation of your purchase. The required documentation typically includes pharmacy receipts, prescription bottles with labels showing the Hetero/Camber manufacturer, insurance explanation of benefits (EOB) statements, or credit card statements showing purchases of generic valsartan. If you have the original prescription bottles, that is the strongest form of documentation because the label will show the manufacturer, the drug name, the NDC number, the quantity, and the date filled. For those without original packaging, pharmacy records are the next best option.
You can contact your pharmacy (whether local, mail-order, or through your insurance’s mail service) and request records of valsartan prescriptions filled during the eligible period. Many pharmacies maintain records for seven to ten years, so retrieving them is often possible. A practical consideration is that gathering documentation takes time—if you took valsartan sporadically over several years or switched pharmacies, you may need to contact multiple providers. Insurance EOBs can also serve as supporting documentation, particularly for mail-order prescriptions or those filled through insurance portals. Compare this to other settlements where claimants must provide original receipts only; this settlement’s acceptance of multiple documentation types is relatively claimant-friendly.
Important Limitations That Could Reduce or Eliminate Your Payment
One of the most critical limitations is the $120 per-person cap, which means that even if you purchased 12 months’ worth of the medication, your total payment cannot exceed $120. Another limitation is the proration issue: if more people file claims than the settlement fund can fully cover, all payments will be reduced proportionally. Additionally, the settlement only covers out-of-pocket costs for the contaminated medication—it does not compensate for any health injuries you may have suffered from taking the contaminated drug. If you developed cancer or another health condition after taking the valsartan, this settlement provides no recovery for those medical expenses or suffering; you would need to pursue a separate personal injury lawsuit, though statute of limitations issues may apply.
A warning: do not assume that simply having taken Hetero valsartan during the contamination period guarantees approval of your claim. The settlement administrator will verify your documentation and cross-reference it against pharmacy records where possible. Claims lacking sufficient documentation or showing no verifiable purchase of Hetero valsartan specifically will be denied. Additionally, if you purchased the medication through a third party—for instance, a family member or caregiver who is not listed as the purchaser—you may face challenges in proving you are the rightful claimant. The settlement requires that you show you paid money for the medication, either directly or through insurance; if someone else paid for your prescription and your name does not appear on the pharmacy record as the purchaser or patient, your claim could be at risk.
How This Hetero Settlement Fits Into the Larger Blood Pressure Drug Contamination Crisis
The Hetero valsartan settlement is one component of the much larger $15.26 million multi-drug settlement that addresses contamination across three different manufacturers and three different medications. In addition to Hetero valsartan, the settlement covers Aurobindo irbesartan and Vivimed losartan, all of which were contaminated with NDMA during overlapping time periods. Claimants who purchased multiple affected medications during the settlement period can file separate claims for each drug, potentially increasing their total recovery—though the $120 cap applies per person, not per medication, meaning you could claim up to $120 total across all three drugs combined, or up to $40 per medication type depending on how the settlement administrator interprets the cap structure.
The broader contamination event affected millions of Americans, as generic blood pressure medications are among the most widely prescribed drugs in the country. Valsartan alone was taken by approximately 4 million Americans at the time of the recall. The multi-drug settlement addressing Hetero, Aurobindo, and Vivimed products represents the FDA’s effort to compensate consumers across multiple manufacturers who experienced the same quality control failures.
What Settlement Administrators Learned From Past Drug Contamination Cases
Previous settlements involving pharmaceutical contamination have shown that claiming typically takes several months to process fully, even after the final approval hearing. Claimants should expect that if their claim is approved, they may not receive payment until late 2026 or early 2027, depending on the volume of claims filed and the settlement administrator’s processing capacity. The longer the wait between the deadline and the final payout, the greater the chance of complications or delays—claim administrators have to verify thousands of pieces of documentation, cross-reference pharmacy records, and identify potential fraud.
In the largest past pharmaceutical settlements, processing has taken six months to a year or more after the final approval hearing. One forward-looking insight from previous settlements is that settlement administrators have increasingly required claimants to provide pharmacy contact information so the administrator can verify claims directly with pharmacies, rather than relying solely on claimant-provided documentation. This is good news for those with clear pharmacy records but potentially problematic for those who obtained medication through channels that no longer exist or whose records have been purged. The Hetero settlement may use similar verification methods, which means having your pharmacy’s name, location, and the approximate date filled will be extremely helpful.
Conclusion
The Hetero valsartan settlement provides compensation to purchasers of a contaminated generic blood pressure medication, offering payments of up to $40 per 30-day supply with a maximum of $120 per person. If you purchased Hetero valsartan between January 1, 2016 and the present, gather your pharmacy receipts, prescription bottles, insurance statements, or pharmacy records immediately and file your claim by the June 2, 2026 deadline. This deadline is absolute—claims submitted even one day late will be rejected without exception.
To move forward, visit the official settlement website, download and complete the claim form, attach supporting documentation showing your purchase of Hetero valsartan, and submit everything before June 2, 2026. Keep copies of everything you send for your records. While the payment cap and potential proration mean your recovery will be limited, this settlement does provide some financial relief for those who took a contaminated medication through no fault of their own. Act now to ensure you do not miss this deadline and forfeit your right to compensation.
You Might Also Like
- Aurobindo Blood Pressure Drug Settlement Resolves NDMA Contamination Claims
- Tyson Beef Price-Fixing Settlement Covers Consumers Who Bought Certain Beef Products
- Lakeview Loan Servicing Data Breach Settlement Covers Borrowers Affected by Cyber Incident
Open Settlements You Can Claim Now
Browse current class action settlements accepting claims — several require no proof of purchase: